EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

GLP ‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study

Jisu Park iD, Ju Hwan Kim iD, Yoon Seob Kim iD, Gyeongmin Lim iD, Hong Ji Song iD, Sang Youl Rhee iD, Seonghoon Hwang iD, Daeun Cho iD, Minyoung Kim iD, Bo-Yeon Kim iD, Chang Won Jeong iD, Dae-Yeon Kim iD und 8 weitere

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8649-8659

DOI: 10.1111/dom.71065 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 06.07.2026. Verfasst von Jisu Park und 19 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Liraglutide, Obesity. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Korea Institute of Drug Safety and Risk Management (KIDS), Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly prescribed for weight loss, yet their safety in clinical practice remains uncertain. We evaluated associations between weight‐management semaglutide or liraglutide initiation and safety outcomes in a multicentre cohort. Materials and Methods We used electronic health records from 13 South Korean hospitals (2018–2025) mapped to the OMOP Common Data Model. Adults initiating semaglutide or liraglutide were compared with propensity score‐matched non‐initiators in a new‐user design. Ten safety outcomes were assessed. Site‐specific hazard ratios were estimated using Cox proportional hazards models and combined via meta‐analysis.

Results

After matching, 2357 semaglutide and 6953 liraglutide initiators were compared with 22 602 and 68 001 non‐initiators, respectively. Semaglutide was associated with increased risks of psychiatric disorders overall (hazard ratio 2.02, 95% confidence interval 1.30–3.14), anxiety disorder (2.39, 1.22–4.71), depressive disorder (3.42, 1.51–7.74), gastrointestinal dysmotility or obstruction (3.91, 1.42–10.82), and vision impairment (1.58, 1.04–2.41). Liraglutide was associated with increased risks of psychiatric disorders overall (1.66, 1.36–2.03), anxiety disorder (1.68, 1.45–1.96), depressive disorder (1.51, 1.14–2.00), hepatic impairment (1.46, 1.16–1.83), pancreatobiliary disorder (1.33, 1.09–1.63), pancreatitis/cholangitis/cholelithiasis (1.40, 1.18–1.68), and vision impairment (1.34, 1.16–1.55). Sensitivity analyses were consistent overall, although semaglutide‐associated vision impairment and liraglutide‐associated hepatic impairment were not significant in some analyses.

Conclusions

GLP‐1 RA initiation for weight loss was associated with higher risks of selected psychiatric and gastrointestinal outcomes compared with non‐initiators, with heterogeneity across agents. These findings underscore the importance of careful patient selection and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideObesitySemaglutideAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesGlucagon-Like PeptidesRepublic of KoreaWeight Loss

Stichwörter der Autor:innen

GLP‐1 analogueobservational studypharmaco‐epidemiologyreal‐world evidenceweight management

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesLiraglutideSemaglutide

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Center for Biomedical Informatics Research, Ajou University Medical Center, Suwon, Republic of Korea.
  • Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.
  • Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
  • Department of Data Science, Hallym University, Chuncheon, Republic of Korea.

ORCID-Profile: Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo-Yeon Kim, Chang Won Jeong, Dae-Yeon Kim, Hang A Park, Min-Ho Kim, Seong Hwan Kim, Won-Woo Seo, Woo Jin Kim, Young Sung Suh, Rae Woong Park, Ju-Young Shin

Förderung

  • National Research Foundation of Korea
  • Korea Institute of Drug Safety and Risk Management (KIDS)
  • Ministry of Food and Drug Safety

Zitieren

APA

Park, J., Kim, J. H., Kim, Y. S., Lim, G., Song, H. J., Rhee, S. Y., Hwang, S., Cho, D., Kim, M., Kim, B. Y., Jeong, C. W., Kim, D. Y., Park, H. A., Kim, M. H., Kim, S. H., Seo, W. W., Kim, W. J., Suh, Y. S., Park, R. W., & Shin, J. Y. (2026). GLP ‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study. Diabetes, Obesity and Metabolism, 28(9), 8649-8659. https://doi.org/10.1111/dom.71065

Vancouver

Park J, Kim JH, Kim YS, Lim G, Song HJ, Rhee SY, et al. GLP ‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study. Diabetes, Obesity and Metabolism. 2026;28(9):8649-8659. doi:10.1111/dom.71065

BibTeX
@article{Park2026,
  author = {Park, Jisu and Kim, Ju Hwan and Kim, Yoon Seob and Lim, Gyeongmin and Song, Hong Ji and Rhee, Sang Youl and Hwang, Seonghoon and Cho, Daeun and Kim, Minyoung and Kim, Bo-Yeon and Jeong, Chang Won and Kim, Dae-Yeon and Park, Hang A and Kim, Min-Ho and Kim, Seong Hwan and Seo, Won-Woo and Kim, Woo Jin and Suh, Young Sung and Park, Rae Woong and Shin, Ju-Young},
  title = {GLP ‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8649--8659},
  doi = {10.1111/dom.71065}
}
Kostenlos starten →